Acquisition Advances XRHealth's Vision for a Connected Healthcare Ecosystem, Extending Personalized Care Across AR and VR Glasses, Smartphones, Smartwatches and Other Digital Devices
BOSTON, Nov. 9, 2026 /PRNewswire-PRWeb/ -- XRHealth, the leading platform for therapeutic technologies, today announced the acquisition of PursueCare, a virtual healthcare provider delivering personalized addiction treatment for alcohol, opioids, cannabis, kratom and 7-OH, and co-occurring mental health conditions. The acquisition includes PursueCare's multidisciplinary telehealth clinical services and FDA-authorized prescription digital therapeutics RESET® and RESET-O®. The acquisition further advances XRHealth's vision for a connected healthcare ecosystem that extends personalized care across AR and VR glasses, smartphones, smartwatches, and other digital devices.
In 2025, 44.6 million Americans aged 12 or older had a substance use disorder, and 89% received no substance use treatment, according to SAMHSA's national survey. Behavioral health provider shortages, stigma, and cost constraints can make treatment difficult to sustain. Fragmented services and gaps between appointments or care settings can leave patients without the comprehensive, engaging care that recovery requires. PursueCare was founded to help remove these barriers through compassionate, judgment-free treatment designed around the realities of patients' lives.
"Substance use disorders require care that is personalized, continuous, and accessible, yet too often patients face barriers to receiving the right support at the right time," said Eran Orr, Founder and CEO of XRHealth. "The acquisition of PursueCare brings together two complementary approaches to healthcare delivery, combining PursueCare's expertise in virtual addiction treatment with XRHealth's technology-driven approach to personalized care. Together, we are expanding our connected healthcare ecosystem to address a broader range of conditions and give patients greater flexibility in how and where they receive care. For instance, someone struggling with an addiction can access care at the exact moment of need to prevent a further relapse. Our vision is to make personalized healthcare more accessible and seamlessly connected across the digital devices people use every day."
Through the acquisition of PursueCare, XRHealth will provide patients with access to licensed addiction clinicians, therapists, counselors, psychiatrists, and case managers through secure telehealth and mobile-based services. This model connects patients with care teams directly from a smart phone app, reaching beyond limited community resources, and reducing the long wait time, travel, time off work, and childcare arrangements that can make ongoing treatment difficult.
PursueCare's care model combines medical care, behavioral health, medications, and software-based treatments tailored to each patient's needs. Services may include medications for opioid use disorder, therapy and counseling, cognitive behavioral therapy (CBT), psychiatric care, and case management to address transitions from hospitals, prisons, and other treatment settings and connect patients with community resources for primary care, housing, transportation, food security, and other common barriers.
XRHealth has also acquired PursueCare's FDA-authorized prescription digital therapeutics, RESET® and RESET-O®, which deliver evidence-based cognitive behavioral therapy and contingency management through a smartphone. RESET® is indicated to increase abstinence and treatment retention in adults with substance use disorder, as an adjunct to contingency management. RESET-O® is indicated to increase retention in outpatient treatment for adults with opioid use disorder by providing cognitive behavioral therapy alongside treatment that includes buprenorphine and contingency management, under clinician supervision. Patients can use these software-based treatments to practice recovery skills between visits, while clinicians can review engagement and patient-reported progress. These prescribed therapies advance XRHealth's vision for connected care by extending therapeutic support and the reach of care teams beyond scheduled appointments.
"PursueCare was founded on the belief that treatment should be easier to access, more personalized and designed around the realities of each patient's life," said Nicholas Mercadante, Founder and CEO of PursueCare. "Patients need compassionate care teams and continuous support that is manageable around everyday life. Joining XRHealth gives us an opportunity to build on that mission by connecting our virtual treatment expertise with an expanding ecosystem of digital and immersive healthcare technologies. This combination creates new opportunities to support people throughout their recovery journey while making high-quality care available wherever patients are."
By joining XRHealth, PursueCare will become part of an established virtual care ecosystem that includes immersive VR support groups, where patients can use avatars to participate with greater privacy and anonymity. This creates new opportunities to combine PursueCare's personalized addiction care with XRHealth's immersive VR support groups and expand how patients engage with treatment and peer support.
About XRHealth
XRHealth is the leading platform for therapeutic technologies, delivering FDA-registered immersive devices, evidence-based digital therapeutic programs, mobile care tools, and peer community support to patients living with chronic physical, cognitive, and behavioral health conditions. XRHealth is licensed across 40 U.S. states and serves patients through Medicare Part B, VA programs, and expanding commercial insurance pathways. Learn more at xr.health.
About PursueCare
PursueCare provides personalized virtual addiction and co-occurring mental health treatment in CT, KY, ME, NH, OH, and WV. Its mission is to remove barriers to compassionate, comprehensive care and help people build lasting recovery. Its multidisciplinary team provides medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O® supports treatment outcomes alongside outpatient care. PursueCare accepts private insurance, Medicare, and Medicaid. Learn more pursuecare.com and reachforreset.com. For referrals, email [email protected] or call 866.744.1930.
RESET® Indications for Use
RESET® is a prescription-only digital therapeutic that delivers cognitive behavioral therapy alongside contingency management for adults aged 18 and older receiving clinician-supervised outpatient treatment for substance use disorder. It is intended to increase abstinence during treatment and retention in the outpatient treatment program. The labeled treatment course is 12 weeks (90 days). RESET® is indicated for patients who are not receiving opioid replacement therapy, whose substance use is not limited to alcohol, and for whom opioids are not the primary substance of abuse.
RESET® Important Safety Information
RESET® supplements outpatient care; it does not replace a clinician, outpatient treatment or prescribed medication. Patients should continue their medications as directed. Its benefit without contingency-management incentives has not been evaluated.
RESET® must not be used for emergency or urgent communications. It cannot alert clinicians to an emergency. Anyone experiencing thoughts of harming themselves or others should call 911 or seek immediate care at an emergency department.
Users should primarily speak English, read at approximately a seventh-grade level or higher, and be comfortable using smartphone applications. A compatible Android or iOS smartphone or tablet and periodic internet or wireless access are needed to upload information.
Abstinence benefits beyond the 12-week (90-day) treatment period have not been evaluated. Whether RESET® prevents relapse after treatment ends has not been studied. Effectiveness has not been demonstrated for patients whose primary substance of abuse is opioids. Safety and effectiveness have not been established for patients enrolled in opioid treatment programs.
RESET-O® Indications for Use
RESET-O® is a prescription-only digital therapeutic with a 12-week (84-day) treatment course. It delivers cognitive behavioral therapy to increase retention in outpatient treatment for adults aged 18 and older with opioid use disorder. Patients must be under clinician supervision, and treatment must include transmucosal buprenorphine and contingency management.
RESET-O® Important Safety Information
RESET-O® supplements opioid use disorder treatment; it is not a standalone treatment or a replacement for clinical care, outpatient treatment or prescribed medication. Patients should continue taking medication as instructed by their clinician.
RESET-O® must not be used for emergency or urgent communications. It cannot alert clinicians to an emergency. Anyone experiencing thoughts of harming themselves or others should call 911 or seek immediate care at an emergency department.
Users should primarily speak English, read at approximately a seventh-grade level or higher, and be comfortable using smartphone applications. A compatible Android or iOS smartphone or tablet and periodic internet or wireless access are needed to upload information.
Benefits beyond the 12-week (84-day) treatment period have not been evaluated. Whether RESET-O® prevents relapse after treatment ends has not been studied.
This release is not a complete guide to the safe and effective use of either product. Please consult the full product labeling and Indications for Use and Important Safety Information.
Sources for review: RESET FDA decision summary, pages 1–2; RESET-O FDA indication, PDF page 3; published product safety information.
Media Contact
DeeDee Rudenstein, XRHealth, 1 2675219654, [email protected], https://www.xr.health/
SOURCE XRHealth
Share this article